Houston's Avance Biosciences announces another expansion, this time focused on cell-based assays
With its foot in the door of biotech’s burgeoning cell and gene therapy industry, Houston’s Avance Biosciences is taking advantage of what it says is a “rapidly growing” demand for its services.
The CRO announced Tuesday that it will add 5,500 square feet to its Texas headquarters to focus on cell-based assay services.
“We take a partnership approach with our clients and that means an extended relationship; from discovery to development to clinical testing and on to manufacturing,” Avance CEO Xuening Huang said in a statement. “Our most recent expansions will ensure that we can keep pace with our customer’s increased needs when ramping up development and manufacturing activities.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.